Glioblastoma remains the most aggressive primary brain tumor in adults, with median survival of 14-16 months under standard care, yet personalized immunotherapy has emerged as a transformative treatment approach achieving significantly improved outcomes at specialized cancer centers. TL;DR Yes, cancer centers including Pi Cancer Care now offer personalized immunotherapy for glioblastoma patients through dendritic cell therapy, CAR-T cell protocols, and tumor-specific vaccine